Special Issue "Inflammation, Immunity, and Cancer Progression"
Deadline for manuscript submissions: 31 May 2024 | Viewed by 9921
Interests: animal health; diagnosis; immunology; parasitology; animal nutrition
Interests: basic mechanisms of cancer progression, health disparities, pre-clinical drug development; miRNA; lncRNAs; snoRNAs; nano-technology therapies; antibody-drug conjugates, and exosome-mediated drug delivery
Chronic inflammation plays a significant role in cancer initiation, progression, metastasis, and chemoresistance. Additionally, cancer-related inflammation is the seventh hallmark of cancer and is associated with genetic instability. Genomic and epigenomic mechanisms are essential to establishing cellular programs in cancer and immune cells. The dysregulation of these mechanisms contributes to tumor growth. Transcriptional and epigenetic changes during inflammatory conditions have revealed histone modifications and transcriptional signatures that define dysregulation of cellular function in cancer and immune cells. Eventually, discovering a core set of regulators, such as transcription factors, epigenetic regulatory molecules, and signaling molecules, that can regulate functions in these cells may be sufficient to help reprogram terminally differentiated immune cells. Such findings are certainly having an impact on immune cell-based therapies.
Recent advances in cancer and immune cell genomics and immune cell engineering have therapeutic implications and provide discourse on the challenges, perspectives, and outstanding questions for the emerging role of transcriptional, epigenetic, and metabolic regulation in cancer and immunity.
This Special Issue will highlight the latest experimental advances and technical developments in genomics and epigenomics, gene editing, gene delivery, and therapeutic approaches for studying immune regulation in immune-mediated diseases, including autoimmunity and cancer. The goal is to cover this broad field through a series of high-quality, multidisciplinary research articles discussing overlapping subjects in transcriptional and epigenetic regulation of inflammation during cancer and immunity. We will consider original research, methodology, review articles, and short reports.
Manuscript submissions presenting outstanding contributions to cancer and immunity fields, including, but not limited to, the following topics:
- Inflammation in cancer immunity;
- Transcriptional and epigenetic regulations in cancer cells and immune cell differentiation and development;
- Transcriptomics and epigenomics of immune-mediated diseases;
- Pharmacogenomic of diseases;
- Integration of Bioinformatics Data.
Dr. Deepak Parashar
Dr. Vivek K. Kashyap
Dr. Subhash Tripathi
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer immunity
- bioinformatics data